Table 1.
Comparison of clinical characteristics between non-relapsed and relapsed ALL.
| Non-Relapsed ALL (n = 105) |
Relapsed ALL (n = 34) |
||
|---|---|---|---|
| Median age at diagnosis (range) | 5.0 (0.5–17.0) | 9.5 (0.1–18.0) | 0.176 |
| Median WBC at diagnosis, 109/L (range) | 10.5 (0.6–339) | 25.5 (0.9–630) | <0.001 |
| NCI risk group, n (%) | |||
| Standard risk | 62 (59.1) | 11 (32.3) | |
| High risk | 43 (40.9) | 23 (67.7) | 0.016 |
| Overall risk group, n (%) | |||
| Low risk | 28 (26.6) | 3 (8.8) | |
| Standard risk | 26 (24.7) | 10 (26.4) | |
| High risk | 22 (20.9) | 7 (20.5) | |
| Very high risk | 29 (27.6) | 14 (38.2) | 0.066 |
| Steroid response, n (%) | |||
| Good | 91 (81.6) | 19 (55.8) | |
| Poor | 10 (9.5) | 5 (14.7) | |
| Unknown | 4 (3.9) | 10 (29.5) | 0.475 |
| Recurrent genetic abnormalities, n (%) | |||
| High hyperdiploidy | 24 (22.8) | 5 (14.7) | |
| ETV6-RUNX1 | 29 (27.6) | 4 (11.7) | |
| KMT2A-rarrangement | 3 (2.8) | 3 (8.8) | |
| TCF3-PBX1 | 5 (4.7) | 2 (5.8) | |
| Hypodiploidy | 1 (0.9) | 1 (2.9) | |
| Not detedted | 43 (40.9) | 19 (52.1) | 0.210 |
| IKZF1 deletion, n (%) | 4 (3.8) | 6 (17.6) | <0.001 |
| RAS pathway mutation | 31 (29.5) | 12 (35.2) | 0.830 |
Abbreviation: ALL, acute lymphoblastic leukemia; WBC, white blood count; NCI, national cancer institute.